United States· US:69306-075_cd092b93-57b8-bffc-e053-2a95a90a1a77
Cyclobenzaprine Hydrochloride
A cyclobenzaprine product containing cyclobenzaprine hydrochloride, registered in United States by Doc Rx. The same ATC class is registered in 3 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Cyclobenzaprine is registered in 3 of 19 countries.
Countries holding a registration under ATC M03BX08 (cyclobenzaprine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 2 of them publish a price we can compare per daily dose
Cyclobenzaprine · ATC M03BX08
3 / 19 countries
- Canada
- Norwayprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- Cyclobenzaprine Hydrochloride
- Manufacturer
- Doc Rx
- Country
- United States (US)
- ATC code
- M03BX08
- ATC class
- Cyclobenzaprine
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc11693060750990 TABLET, FILM COATED in 1 BOTTLE (69306-075-09)
Regulatory notes
Interactions
319 interactions on record for cyclobenzaprine.
Graded by severity as the source publishes them — 20 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cyclobenzaprine · interactions on record
319 records
- 20 severe
- 113 moderate
- 1 minor
- 185 info
Most severe, free to view
- FenfluramineA08AA02severe
- DexfenfluramineA08AA04severe
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cyclobenzaprine in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaAG-CYCLOBENZAPRINEANGITA PHARMA INC.
- SpainYURELAX 10 mg CAPSULAS DURASViatris Healthcare Limited
- NorwayCyclobenzaprine HCl solcoSolco
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Spain · Yurelax
- Italy · Flexiban
- Portugal · Flexiban, Miodia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc55bc6d-7463-4a98-b326-93382446098d GET /v1/drugs/dc55bc6d-7463-4a98-b326-93382446098d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "0VE05JYS2P",
"rxcui": "52101",
"inchikey": "VXEAYBOGHINOKW-UHFFFAOYSA-N",
"display_name": "CYCLOBENZAPRINE HYDROCHLORIDE",
"substance_type": "chemical",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "ORAL",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"spl_meta": {
"fe81c68d-a579-4fe9-e053-6294a90a7bc0": {
"match": "brand_token",
"title": "CYCLOBENZAPRINE HYDROCHLORIDE TABLET, FILM COATED [ST. MARY'S MEDICAL PARK PHARMACY]",
"spl_version": "8",
"published_date": "2026-06-01"
}
},
"productid": "69306-075_cd092b93-57b8-bffc-e053-2a95a90a1a77",
"productndc": "69306-075",
"dosage_form": "TABLET, FILM COATED",
"orange_book": {
"appl_no": "078722",
"products": [
{
"rs": false,
"rld": false,
"te_code": null,
"strength": "5MG",
"product_no": "001",
"approval_date": "May 12, 2008"
},
{
"rs": false,
"rld": false,
"te_code": null,
"strength": "7.5MG",
"product_no": "002",
"approval_date": "May 12, 2008"
},
{
"rs": false,
"rld": false,
"te_code": null,
"strength": "10MG",
"product_no": "003",
"approval_date": "May 12, 2008"
}
],
"appl_type": "A"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "CYCLOBENZAPRINE HYDROCHLORIDE",
"proprietary_name": "Cyclobenzaprine Hydrochloride",
"active_ingred_unit": "mg/1",
"application_number": "ANDA078722",
"marketing_category": "ANDA",
"nonproprietary_name": "Cyclobenzaprine Hydrochloride",
"start_marketing_date": "20180116",
"active_numerator_strength": "7.5"
}See everything about cyclobenzaprine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.